Clinical trials
High Risk clinical trials
Below are recruiting high risk clinical trials, each written for real people, not researchers. We’re tracking 922 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT03152058RecruitingPhase 2
Certolizumab for pregnancy in people with APS
This Phase 2 study tests whether certolizumab can improve pregnancy outcomes in people with antiphospholipid syndrome (APS). It targets pregnancy complications related to APS while closely checking safety, infections, and certain health conditions.
New York, New YorkAges 18–40 - NCT02775461Recruiting
Registry for people at high risk for pancreatic cancer
This study is a registry (a way to track health over time) for people with a strong family history or certain inherited genetic risks for pancreatic cancer. It may help doctors learn how best to monitor and protect high-risk people, and to see who benefits most from follow-up.
New York, New YorkAges 18 years+ - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT02437981Enrolling by invitation
PrEP for HIV prevention in high-risk adults in Thailand
This trial checks how well PrEP pills (TDF/FTC) prevent HIV in people who are at high risk and are HIV-negative. It may help you understand whether PrEP is a good prevention option for your situation.
Bangkok, PathumwanAges 18 years+ - NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
Baltimore, MarylandAges 1–50 - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT00009633Recruiting
Follow-up care for very premature infants born at specialized hospitals
This study follows babies born very early (before 27 weeks of pregnancy) who were treated at specialized neonatal centers. Researchers track their health and development over time to better understand how to care for extremely premature infants.
Birmingham, AlabamaAges 1.5 years–2.2 years - NCT00870129Recruiting
MRI mapping to plan radiation for certain brain tumors
This study uses MRI scans to find higher-risk areas in certain brain and other solid tumors and help plan radiation treatment. It also looks for changes in tumor “metabolites” (chemicals in the tumor) that may relate to how the tumor behaves.
New York, New YorkAges 18 years+ - NCT00796146Recruiting
Study people newly infected with HIV to learn early changes
This study enrolls adults with a very recent (“acute”) HIV infection to follow them over time and better understand what happens early after infection. Your participation may help researchers improve how acute HIV is detected and managed.
Bangkok, BangkokAges 18 years+ - NCT00898313Recruiting
Study looks for cancer clues in people at high risk for lung cancer
This study enrolls adults who are being checked for possible lung cancer because of concerning symptoms or a high-risk situation. It aims to find molecular (cell/DNA-related) predictors that may help doctors better recognize lung cancer earlier.
Nashville, TennesseeAges 18 years+ - NCT00040352Recruiting
Melanoma risk in families and individuals
This study looks at people and families with a high risk of melanoma, especially if it runs in the family or is linked to certain genetic conditions. The goal is to better understand what causes melanoma and how to detect it earlier.
Bethesda, MarylandAges 4 weeks–99 years - NCT06215326Recruiting
Short-term exercise before lung cancer surgery
This trial tests if doing exercise before lung cancer surgery can help people with moderate-to-high risk. Participants will exercise for a short period to see if it improves their recovery.
Guangzhou, GuangdongAges 18 years+ - NCT05577988RecruitingPhase 3
Genetic-guided weaker blood thinner vs stronger standard therapy
This study tests whether switching early to a weaker anti-platelet medicine based on your genetics can reduce bleeding problems in people at high risk for bleeding after a heart attack. It compares this approach to the usual strategy of staying on a stronger anti-platelet medicine.
Paris, IDFAges 18 years+ - NCT06000943Recruiting
Bleeding and clot risk after heart valve procedure
This study looks at patients who had a TAVR procedure (a new valve put in the heart) to understand their risk of bleeding or clots over the next year. It tracks changes in blood thinner medications at 1 month, 90 days, and 1 year to help doctors personalize care.
AalstAges 18 years+ - NCT07252830Recruiting
Finding hidden heart risk with extra imaging tests
This study looks at whether using special scans of the heart and neck arteries can better find people at very high risk for heart problems, compared to just using a standard risk score. You may be eligible if you have high cholesterol and are seeing a heart doctor.
PoitiersAges 40–80 - NCT07223385RecruitingPhase 2
Heart health check for prostate cancer patients on ARPI therapy
This trial is for men with advanced prostate cancer who are taking ARPI therapy. It offers a special heart health consultation to help manage the increased heart risk that can come with these powerful cancer treatments.
Los Angeles, CaliforniaAges 45 years+ - NCT04432220RecruitingPhase 4
Taking blood thinners one year after atrial fibrillation ablation
This study looks at whether people who have stayed in normal rhythm one year after atrial fibrillation ablation should continue blood thinning treatment. It may help guide safer, more personalized choices about long-term blood thinners after a successful procedure.
SeoulAges 19–80 - NCT05262803RecruitingPhase 4
Lower blood-thinner dose after heart attack for high bleeding risk
This Phase 4 study tests whether using a reduced blood-thinner (antithrombotic) strategy after a heart attack can lower bleeding without losing heart protection. It is mainly for people considered high risk for bleeding after getting a stent.
AalborgAges 18 years+ - NCT07721649Recruiting
Flu shot during hospital stay for heart patients
This study checks if giving a flu shot to heart patients while they are in the hospital helps prevent heart problems later. It tests whether the flu shot can reduce the risk of further heart events.
CologneAges 18 years+ - NCT07645391Recruiting
Early Detection Program for Men at High Genetic Risk for Prostate Cancer
This study aims to find prostate cancer early in men who have a genetic predisposition (inherited genetic mutations or strong family history) that puts them at higher risk. The goal is to detect it sooner, when treatment may be more effective.
Ann Arbor, MichiganAges 35–70 - NCT07479056Recruiting
Fexuprazan to prevent stomach bleeding in heart patients on two blood thinners
This trial tests whether fexuprazan can prevent upper gastrointestinal bleeding in people at high risk who need two antiplatelet drugs for at least 6 months after a heart stent. If you are on dual antiplatelet therapy after a stent and have risk factors like older age, low weight, or history of ulcers, this study may help protect your stomach.
Seoul, Eunpyeong-guAges 20 years+
Hear when a new High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk?
- Yes. Clin2 currently lists 922 recruiting high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.